Aura Biosciences (AURA)
(Delayed Data from NSDQ)
$6.08 USD
-0.18 (-2.88%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $6.06 -0.02 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AURA 6.08 -0.18(-2.88%)
Will AURA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AURA based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AURA
AURA falls 2.88% on September 19, leaving the technical picture intact
Pocket Pivot appears for AURA after 2.62% move
Aura Energy Reports Financial Loss, Focuses on Advancing Key Projects
Is AURA building bearish momentum? 20 Day Moving Average Resistance shows up after slipping 3.02%
AURA forms Bullish Engulfing on September 16